| Literature DB >> 35709136 |
Dalal Al-Taweel1, Samuel Koshy1, Sara Al-Ansari2, Asmaa Al-Haqan1, Bedoor Qabazard3.
Abstract
Antidote stocking represents a major challenge to hospitals all over the world, including Kuwait. In order to assist hospitals to reduce costs and improve patient care, an essential antidote list can be used as an initial foundation for securing sufficient antidote availability at healthcare institutions. The aim of our study is to generate a nationally relevant essential antidote list for emergency care hospitals in Kuwait using the e-Delphi method by establishing consensus through a multidisciplinary expert group of healthcare providers. An electronic survey with 47 essential antidotes was developed. The e-Delphi method was used, with three rounds of voting, to determine expert consensus on an essential antidote list for hospitals in Kuwait. A purposive sample of healthcare professionals from governmental and private hospitals were selected for this study (n = 30). Consensus was gained if ≥75% of the expert panel agreed on the inclusion of the antidote, without any strong disagreements. Round 1 of the e-Delphi resulted in 41 antidotes reaching consensus and seven new antidotes suggested by the expert panel. Round 2 had two antidotes (out of seven newly suggested ones) reaching consensus. Round 3 was a confirmatory round, where the expert group agreed on their previous rounds' opinions. This resulted in the development of an essential antidote list with 43 antidotes. The optimal approach for ensuring adequate availability of antidotes is continuous monitoring of local poisoning incidence and antidote requirements through collaborations between academic researchers and emergency care clinicians. The development of an essential antidote list, with expert consensus, is one of the initial steps in securing a foundation for appropriate provision of antidotes at all healthcare institutions. This is the first study that the authors are aware of that demonstrates that the e-Delphi technique can consolidate recommendations of experts in emergency medicine to provide a list of essential antidotes.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35709136 PMCID: PMC9202922 DOI: 10.1371/journal.pone.0269456
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Demographics of experts in Rounds 1, 2 and 3.
| Demographics | Round 1 (n = 22) | Round 2 (n = 22) | Round 3 (n = 20) |
|---|---|---|---|
|
| |||
| Male | 16 | 16 | 14 |
| Female | 6 | 6 | 6 |
|
| |||
| Governmental | 13 | 13 | 12 |
| Private | 8 | 8 | 7 |
| Other | 2 | 2 | 2 |
|
| |||
| Emergency Medicine | 15 | 15 | 13 |
| Pharmacy | 3 | 3 | 3 |
| Pediatrics | 4 | 4 | 4 |
| ICU | 1 | 1 | 1 |
| Medical Toxicology | 1 | 1 | 1 |
|
| |||
| Resident | 1 | 1 | 1 |
| Registrar | 0 | 0 | 0 |
| Assistant Registrar | 0 | 0 | 0 |
| Senior Registrar | 7 | 7 | 5 |
| Specialist | 3 | 3 | 3 |
| Senior Specialist | 3 | 3 | 3 |
| Consultant | 5 | 5 | 5 |
| Pharmacist | 3 | 3 | 3 |
*Aggregates are more than the sample number as some experts worked in two sites/specialties.
Fig 1Step-by-step process of developing the expert consensus list of essential antidotes.
Consensus level of each antidote in each Delphi round.
| No | Antidote | Toxic exposure | Round 1 | Round 2 | Round 3 |
|---|---|---|---|---|---|
| n = 22 | n = 22 | n = 20 | |||
| 1 | Acetylcysteine IV | Acetaminophen | 100% | - | - |
| 2 | Acetylcysteine PO | Acetaminophen | 81.8% | 81.8% | - |
| 3 | Activated charcoal PO | Oral poisons bound to charcoal | 100% | - | - |
| 4 | Atropine sulfate | Organophosphorus bradycardia | 100% | - | - |
| 5 | Calcium chloride | Calcium channel blockers, hypermagnesemia, hyperkalemia | 100% | - | - |
| 6 | Calcium gluconate | Hydrofluoric acid burns | 95.4% | - | - |
| 7 | Calcium gluconate gel | Hydrofluoric acid burns | 95.4% | - | - |
| 8 | Dicobalt edetate | Cyanide | 81.8% | 63.6% | - |
| 9 | Hydroxocobalamin (Cyanokit®) | Cyanide | 100% | - | - |
| 10 | Sodium nitrite | Cyanide | 81.8% | - | - |
| 11 | Sodium thiosulphate | Cyanide | 81.8% | - | - |
| 12 | Flumazenil | Over-sedation with benzodiazepines | 100% | - | - |
| 13 | Glucagon | Beta Blockers/Calcium Channel Blockers | 100% | - | - |
| 14 | Dextrose | Calcium channel blockers cardiotoxicity reversal, | 100% | - | - |
| 15 | Lipid Emulsion (Intralipid 20%) | Severe, systemic local anaesthetic toxicity | 90.9% | - | - |
| 16 | Methylthioninium chloride (methylene blue) | Methaemoglobinaemia | 100% | - | - |
| 17 | Naloxone (Narcan®) | Opioids | 100% | - | - |
| 18 | Procyclidine injection | For Extrapyramidal symptoms | 86.4% | - | - |
| 19 | Sodium bicarbonate | Tricyclic antidepressants | 100% | - | - |
| 20 | Thiamine (Vit. B1) | Ethanol toxicity | 90.9% | - | - |
| 21 | Antisnake antivenin | Snake venoms | 95.4% | - | - |
| 22 | Antiscorpion antivenin | Scorpion venoms | 95.4% | - | - |
| 23 | Black widow spider antivenin | Black widow spider venom | 59.1% | 68.2% | - |
| 24 | Bromocriptine mesylate (Parlodel®) | Drugs causing Neuroleptic Malignant Syndrome | 86.4% | - | - |
| 25 | Calcium folinate | Methotrexate/Methanol toxicity | 77.3% | - | - |
| 26 | Cyproheptadine | Drugs causing serotonin syndrome | 86.4% | - | - |
| 27 | L-Carnitine | Valproic acid | 91.0% | - | - |
| 28 | Dantrolene | Drugs causing Neuroleptic Malignant Syndrome | 91.0% | - | - |
| 29 | Desferrioxamine (Desferal®) | Iron | 100% | - | - |
| 30 | Digoxin specific antibody fragments fab | Digoxin | 100% | - | - |
| 31 | Fomepizole | Ethylene glycol | 100% | - | - |
| 32 | Ethanol IV | Ethylene glycol | 72.7% | 77.3% | - |
| 33 | Idarucizumab | Dabigatran | 91.0% | - | - |
| 34 | PEG solution | Whole bowel irrigation | 91.0% | - | - |
| 35 | Mesna | Cyclophosphamide | 72.8% | 63.6% | - |
| 36 | Octreotide acetate (Sandostatin) | Sulphonylureas, hypoglycemia | 95.5% | - | - |
| 37 | Pralidoxime | Organophosphate insecticides | 100% | - | - |
| 38 | Phentolamine | Digital ischaemia, Resistant hypertension | 81.8% | - | - |
| 39 | Phytomenadione IV (Vitamin K1) | Warfarin | 100% | - | - |
| 40 | Phytomenadione PO (Vitamin K1) | Warfarin | 86.4% | - | - |
| 41 | Protamine sulphate | Heparin & low molecular weight heparins | 100% | - | - |
| 42 | Pyridoxine (Vitamin B6) | Isoniazid seizures | 95.4% | - | - |
| 43 | Calcium disodium EDTA | Heavy metals: particularly lead, zinc | 81.8% | - | - |
| 44 | Physostigmine | Atropine | 81.8% | - | - |
| 45 | Potassium iodide | Radioactive iodine | 86.4% | - | - |
| 46 | Succimer (dimercaptosuccinic acid) | Lead and mercury | 81.8% | - | - |
| 47 | Prussian blue | Thallium, radioactive cesium | 72.8% | 72.7% | - |
| 48 | Sugammadex | Neuromuscular blockade drugs | - | 100% | - |
| 49 | Unithiol | Heavy metals, particularly mercury | - | 72.7% | 65% |
| 50 | Glucarpidase | Methotrexate | - | 72.8% | 65% |
| 51 | Hyperbaric Oxygen therapy | Carbon monoxide | - | 86.4% | 85%* |
| 52 | Prothrombin complex concentrate | Reversal of acquired coagulation factor deficiency | - | 95.4% | - |
| 53 | Uridine triacetate | fluorouracil or capecitabine overdose | - | 59.1% | 50% |
| 54 | Calcium trisodium | Contamination with plutonium, americium or curium | - | 63.6% | 50% |
* Had a minimum of one expert with strong disagreement.
Final list of essential antidotes for hospitals that provide emergency care services in Kuwait.
| No. | Antidote | Toxic exposure |
|---|---|---|
| 1 | Acetylcysteine IV | Acetaminophen |
| 2 | Activated charcoal PO | Oral poisons bound to charcoal |
| 3 | Atropine sulfate | Organophosphorus bradycardia |
| 4 | Calcium chloride | Calcium channel blockers, hypermagnesemia hyperkalemia |
| 5 | Calcium gluconate | Hydrofluoric acid burns |
| 6 | Calcium gluconate gel | Hydrofluoric acid burns |
| 7 | Hydroxocobalamin (Cyanokit®) | Cyanide |
| 8 | Sodium nitrite | Cyanide |
| 9 | Sodium thiosulphate | Cyanide |
| 10 | Flumazenil | Over-sedation with benzodiazepines |
| 11 | Glucagon | For beta blockers/calcium channel blockers |
| 12 | Dextrose | Calcium Channel Blockers cardiotoxicity reversal |
| 13 | Lipid Emulsion (Intralipid 20%) | Severe, systemic local anaesthetic toxicity |
| 14 | Methylthioninium chloride (methylene blue) | Methaemoglobinaemia |
| 15 | Naloxone (Narcan®) | Opioids |
| 16 | Procyclidine injection | For extra-pyramidal symptoms |
| 17 | Sodium bicarbonate | Tricyclic antidepressants |
| 18 | Thiamine (Vit. B1) | Ethanol |
| 19 | Sugammadex | Neuromuscular blockade drug |
| 20 | Prothrombin complex concentrate | Reversal of acquired coagulation factor deficiency |
| 21 | Antisnake antivenin | Snake venoms |
| 22 | Antiscorpion antivenin | Scorpion venoms |
| 23 | Bromocriptine mesylate (Parlodel®) | Drugs causing Neuroleptic Malignant Syndrome |
| 24 | Calcium folinate | Methotrexate/Methanol |
| 25 | Cyproheptadine | Drugs causing serotonin syndrome |
| 26 | L-Carnitine | Valproic acid |
| 27 | Dantrolene | Drugs causing Neuroleptic Malignant Syndrome |
| 28 | Desferrioxamine (Desferal®) | Iron |
| 29 | Digoxin specific antibody fragments fab | Digoxin |
| 30 | Fomepizole | Ethylene glycol |
| 31 | Idarucizumab | Dabigatran |
| 32 | PEG solution (polyethylene glycol) | Whole bowel irrigation |
| 33 | Octreotide acetate (Sandostatin) | For sulphonylureas, hypoglycemia |
| 34 | Pralidoxime | Organophosphate insecticides |
| 35 | Phentolamine | Digital ischaemia, Resistant hypertension |
| 36 | Phytomenadione IV (Vitamin K1) | Warfarin |
| 37 | Phytomenadione PO (Vitamin K1) | Warfarin |
| 38 | Protamine sulphate | Heparin & low molecular weight heparins |
| 39 | Pyridoxine (Vit. B6) | For isoniazid seizures |
| 40 | Calcium disodium EDTA | Heavy metals particularly lead, zinc |
| 41 | Physostigmine | Atropine poisoning |
| 42 | Potassium iodide | Radioactive iodine |
| 43 | Succimer (dimercaptosuccinic acid) | Chelating agent for lead and mercury |